Stryker Corporation

Report azionario NYSE:SYK

Capitalizzazione di mercato: US$127.5b

Stryker Crescita futura

Criteri Future verificati 2/6

Stryker prevede che gli utili e i ricavi cresceranno rispettivamente di 16.4% e 8% all'anno. Si prevede che l'EPS crescerà di 16.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 21.8% in 3 anni.

Informazioni chiave

16.4%

Tasso di crescita degli utili

16.13%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.4%
Tasso di crescita dei ricavi8.0%
Rendimento futuro del capitale proprio21.81%
Copertura analitica

Good

Ultimo aggiornamento12 Jun 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • May 04

Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...

Recent updates

Aggiornamento della narrazione • Jun 14

SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects

Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.
Aggiornamento della narrazione • May 31

SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential

Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.
Seeking Alpha • May 27

Stryker: Reaching Interesting Levels

Summary Stryker shares have declined 10% since March amid a soft Q1 and cybersecurity concerns, but full-year guidance remains intact. Q1 organic sales growth slowed to 2.4% due to a cyber incident, but management expects 8.0-9.5% organic growth for the full year. Stryker´s bolt-on acquisition of Amplitude Vascular Systems expands cardiovascular exposure, with leverage still manageable at around 2x EBITDA. Valuation has compressed to 20-21x earnings, making current levels more attractive as recovery and guidance reaffirmation signal resilience. Read the full article on Seeking Alpha
Aggiornamento della narrazione • May 14

SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside

Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.
Articolo di analisi • May 04

Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...
Aggiornamento della narrazione • Apr 21

SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside

Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.
Aggiornamento della narrazione • Apr 06

SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside

The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.
Aggiornamento della narrazione • Mar 22

SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside

Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.
Aggiornamento della narrazione • Mar 07

SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside

The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.
Aggiornamento della narrazione • Feb 20

SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside

Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.
Articolo di analisi • Feb 09

Stryker's (NYSE:SYK) Earnings Seem To Be Promising

Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...
Articolo di analisi • Feb 07

Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88

Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...
Aggiornamento della narrazione • Feb 06

SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment

Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.
Aggiornamento della narrazione • Jan 22

SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential

Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.
Aggiornamento della narrazione • Jan 08

SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside

Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.
Aggiornamento della narrazione • Dec 19

SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential

Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.
Articolo di analisi • Dec 14

Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88

Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...
Articolo di analisi • Sep 08

Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Articolo di analisi • Aug 08

Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality

NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...
Articolo di analisi • Jul 09

Estimating The Intrinsic Value Of Stryker Corporation (NYSE:SYK)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Stryker fair value estimate is US$371 With US$390 share price...

Previsioni di crescita degli utili e dei ricavi

NYSE:SYK - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202831,9706,4935,7147,83720
12/31/202729,5825,5444,9116,75326
12/31/202627,2674,8453,6685,01626
3/31/202625,2703,3374,5715,375N/A
12/31/202525,1163,2464,2835,044N/A
9/30/202524,3812,9434,0734,832N/A
6/30/202523,8182,9184,0244,766N/A
3/31/202523,2182,8593,5774,288N/A
12/31/202422,5952,9933,4874,242N/A
9/30/202421,9743,5903,2053,839N/A
6/30/202421,3893,4482,8033,415N/A
3/31/202420,9633,3612,8583,470N/A
12/31/202320,4983,1653,1363,711N/A
9/30/202319,8852,5852,5683,186N/A
6/30/202319,4552,7092,4173,025N/A
3/31/202318,9522,6272,2672,866N/A
12/31/202218,4492,3582,0362,624N/A
9/30/202217,9482,4572,0152,621N/A
6/30/202217,6292,0792,0672,665N/A
3/31/202217,4302,0152,4533,014N/A
12/31/202117,1081,9942,7383,263N/A
9/30/202116,6691,9003,0163,500N/A
6/30/202116,2462,0832,9733,396N/A
3/31/202114,7161,4082,7123,138N/A
12/31/202014,3511,5992,7903,277N/A
9/30/202014,2201,7562,2542,775N/A
6/30/202014,0701,6011,9602,575N/A
3/31/202014,9562,1641,7982,469N/A
12/31/201914,8842,083N/A2,191N/A
9/30/201914,5493,426N/A2,502N/A
6/30/201914,2043,550N/A2,491N/A
3/31/201913,8763,522N/A2,626N/A
12/31/201813,6013,553N/A2,610N/A
9/30/201813,2761,236N/A2,243N/A
6/30/201813,0401,080N/A1,704N/A
3/31/201812,7301,019N/A1,705N/A
12/31/201712,4441,020N/A1,559N/A
9/30/201712,1301,779N/A1,538N/A
6/30/201711,9571,700N/A1,961N/A
3/31/201711,7851,689N/A1,804N/A
12/31/201611,3251,647N/A1,915N/A
9/30/201610,8831,659N/A1,928N/A
6/30/201610,4701,605N/A917N/A
3/31/201610,0621,617N/A781N/A
12/31/20159,9461,439N/A981N/A
9/30/20159,8491,177N/A907N/A
6/30/20159,818933N/A1,940N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di SYK ( 16.4% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di SYK ( 16.4% all'anno) cresceranno più lentamente rispetto al mercato US ( 18.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di SYK cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di SYK ( 8% all'anno) crescerà più lentamente rispetto al mercato US ( 12.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di SYK ( 8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di SYK sarà elevato tra 3 anni ( 21.8 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/29 21:44
Prezzo dell'azione a fine giornata2026/06/29 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Stryker Corporation è coperta da 53 analisti. 26 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays